Business

MCLR: Q2 2025 saw 24% revenue growth, strong margins, and major international orders

MCLR: Q2 2025 saw 24% revenue growth, strong margins, and major international orders

Medclair AbAugust 21, 20255
MCLR: Q2 2025 saw 24% revenue growth, strong margins, and major international orders

About this update from Medclair Ab

Revenue grew 24% year-over-year in Q2 2025, with strong EBITDA margin and expanding international presence. Major orders in healthcare and recycling, plus a strategic entry into pharmaceuticals, support continued growth. Equity ratio remains high at 79%.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Medclair Ab